Agents from amphibians with anticancer properties

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 931-939

  Lu, Chuang Xin ^a   Nan, Ke Jun ^a   Lei, Yan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Amphibians; Anticancer; Bufalin; Peptides; RNase

Indexed keywords

AMPHIBIAN PROTEIN; AMPHINASE; AUREIN; BUFALIN; CITROPIN; EGG PROTEIN; GAEGURIN; MAGAININ DERIVATIVE; PEPTIDE; RANPIRNASE; RIBONUCLEASE; SIALIC ACID BINDING LECTIN; UNCLASSIFIED DRUG;

AMPHIBIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG MECHANISM; FROG; OOCYTE; PRIORITY JOURNAL; REVIEW; SKIN;

ALKALOIDS; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOGENIC AMINES; BUFANOLIDES; BUFONIDAE; MOLECULAR SEQUENCE DATA; RIBONUCLEASES; SKIN;

EID: 54249139787     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283139100     Document Type: Review

References (88)

1. Clarke BT. The natural history of amphibian skin secretions, their normal functioning and potential medical applications. Biol Rev 1997; 72:365-379.
2. Bettin C, Greven H. Bacteria on the skin of Salamandra salamandra (L.) (Amphibia, Urodela) with notes on their possible significance. Zoologischer Anzeiger 1986; 216:267-270.
3. Cevikbas A. Antibacterial activity in the skin secretion of the frog Rana ridibunda. Toxicon 1978; 16:195-197.
4. Daly JW, Myers CW, Whittaker N. Further classification of skin alkaloids from neotropical poison frogs (Dendrobatidae), with a general survey of toxic/noxious substances in the amphibia. Toxicon 1987; 25:1023-1095.
5. Habermehl GG, Krebs HC. Venomous animals and their toxins. Naturwissenschaften 1986; 73:459-470.
6. Ko WS, Park TY, Park C, Kim YH, Yoon HJ, Lee SY, et al. Induction of apoptosis by Chan Su, a traditional Chinese medicine, in human bladder carcinoma T24 cells. Oncol Rep 2005; 14:475-480.
7. Giri B, Gomes A, Debnath A, Saha A, Biswas AK, Dasgupta SC, Gomes A. Antiproliferative, cytotoxic and apoptogenic activity of Indian toad (Bufo melanostictus, Schneider) skin extract on U937 and K562 cells. Toxicon 2006; 48:388-400.
8. Nogawa T, Kamano Y, Yamashita A, Pettit GR. Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. J Nat Prod 2001; 64:1148-1152.
9. Watabe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem 1996; 271:14067-14073.
10. Kawazoe N, Watabe M, Nakay K, Nakajo S, Nakaya K. Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 1999; 18:2413-2421.
11. Watabe M, Kawazoe N, Masuda Y, Nakajo S, Nakaya K. Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 1997;57:3097-3100.
12. Watabe M, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Treatment of U937 cells with bufalin induces the translocation of casein kinase 2 and modulates the activity of topoisomerase II prior to the induction of apoptosis 1. Cell Growth Differ 1997; 8:871-879.
13. Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 1995; 19:549-556.
14. Hasbimoto S, Jing Y, Kawazoe N, Mast Y, Nakajo S, Yoshida T, et al. Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res 1997; 21:875-883.
15. Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S, et al. Selective inhibitory effect of bufalin on growth of human tumour cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 1994; 85:645-651.
16. Jing Y, Watabe M, Hashimoto S, Nakajo S, Nakaya K. Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 1994; 14:1193-1198.
17. Pastor N, Cortés F. Bufalin influences the repair of x-ray-induced DNA breaks in Chinese hamster cells. DNA Repair (Amst) 2003; 2:1353-1360.
18. Yamada K, Hino K-I, Tomoyasu S, Honma Y, Tsuruoka N. Enhancement by bufalin of retinoic acid-induced differentiation of acute promyelocytic leukemia cells in primary culture. Leuk Res 1998; 22:589-595.
19. Kawazoe N, Aiuchi T, Masuda Y, Nakajo S, Nakaya R. Induction of apoptosis by bufalin in human tumour cells is associated with a change of intracellular concentration of Na+ ions1. J Biochem 1999; 126:278-286.
20. Numazawa S, Shinoki MA, Ho H, Yoshida T, Kuroiwa Y. Involvement of Na + ,K(+)-ATPase inhibition in K562 cell differentiation induced by bufalin. J Cell Physiol 1994; 160:113-120.
21. Han K-Q, Huang G, Gu W, Su Y-H, Huang X-Q, Ling C-Q. Anti-tumour activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumour model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2007; 13:3374-3379.
22. Yeh J-Y, Huang WJ, Kan S-F, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003; 54:112-124.
23. Lee DY, Yasuda M, Yamamoto T, Yoshida T, Kuroiwa Y. Bufalin inhibits endothelial cell proliferation and angiogenesis in vitro. Life Sci 1997; 60:127-134.
24. Akiyama M, Ogura M, Iwai M, Iijima M, Numazawa S, Yoshida T. Effect of bufalin on growth and differentiation of human skin carcinoma cells in vitro. Hum Cell 1999; 12:205-209.
25. Zhang LS, Nakaya K, Yoshida T, Kuroiwa Y. Bufalin as a potent inducer of differentialion of human myeloid leukemia cells. Biochem Biophys Res Commun 1991; 178:686-693.
26. Zhang L, Nakaya K, Yoshida T, Kuroiwa Y. Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res 1992; 52:4634-4641.
27. Kamano Y, Kotake A, Hashima H, Inoue M, Morita H, Takeya K. Structure-cytotoxic activity relationship for the toad poison bufadienolides. Bioorg Med Chem 1998; 6:1103-1115.
28. Lee DY, Yasuda M, Yammoto T, Yoshida T, Kuroiwa Y. Bufalin inhibits endothelial cell proliferation and angiogenesis in vitro. Life Sci 1997; 60:127-134.
29. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003; 54:112-124.
30. Pastor N, Domínguez I, Mateos S, Cortés F. A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells. Mutat Res 2002; 515:171-180.
31. Barra D, Simmaco M. Amphibian skin: a promising resource for antimicrobial peptides. Trends Biotechnol 1995; 13:205-209.
32. Chen Y, Xu C, Hong S, Chen J, Liu N, Underhill CB, et al. RGD-tachyplesin inhibits tumour growth 1. Cancer Res 2001; 61:2434-2438.
33. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5:1032-1038.
34. Mai JC, Mi Z, Kim S-H, Ng B, Robbins PD. A proapoptotic peptide for the treatment of solid tumours. Cancer Res 2001; 61:7709-7712.
35. Risso A, Braidot E, Sordano MC, Vianello A, Macri F, Skerlavaj B, et al. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 2002; 22:1926-1935.
36. Cruciani RA, Barker JL, Zasloff M, Chen HC, Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci 1991; 88:3792-3796.
37. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterizationof the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and P-glycoprotein over-expressing tumour cell lines. Anti-Cancer Drug Design 2000; 15:151-160.
38. Sharom FJ, DiDiodato G, Yu X, Ashbourne KJD. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem 1995; 270:10334-10341.
39. Zasloff M. Magainins, a class of antimicrobial peptides from xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci 1987; 84:5449-5453.
40. Park Y, Lee DG, Jang S-H, Woo ER, Jeong HG, Choi CH, Hahm KS. A leu-lys-rich antimicrobial peptide: activity and mechanism. Biochim Biophys Acta (BBA) - Proteins Proteomics 2003; 1645:172-182.
41. Soballe PW, Maloy WL, Myrga ML Jacob LS, Herlyn M. Experimental local therapy of human melanoma with lytic magainin peptides. Int J Cancer 1995; 60:280-284.
42. Baker MA, Maloy WL, Zasloff M, Jacob LS. Anticancer efficacy of magainin 2 and analogue peptides. Cancer Res 1993; 53:3052-3057.
43. Ohsaki Y, Gazdar AF, Chen HC, Johnson BE. Antitumour activity of magainin analogues against human lung cancer cell lines. Cancer Res 1992; 52:3534-3538.
44. Javadpour MM, Juban MM, Lo WCJ, Bishop SM, Alberty B, Cowell SM, et al. De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 1996; 39:3107-3113.
45. Won HS, Seo MD, Jung SJ, Lee SJ, Kang SJ, Son WS, et al. Structural determinants for the membrane interaction of novel bioactive undecapeptides derived from gaegurin 5. J Med Chem 2006; 49:4886-4895.
46. Kim S, Kim SS, Bang Y-J, Kim S-J, Lee BJ. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumour cell lines. Peptides 2003; 24:945-953.
47. Takeshima K, Chikushi A, Lee K-K, Yonehara S, Matsuzaki K. Translocation of analogues of the antimicrobial peptides magainin and bufolin across human cell membranes. J Biol Chem 2003; 278:1310-1315.
48. Westerhoff HV, Hendler RW, Zasloff M, Juretic D. Interactions between a new class of eukaryotic antimicrobial agents and isolated rat mitochondria. Biochim Biophys Acta 1989; 975:361-369.
49. Bechinger B. The structure, dynamics and orientation of antimicribial peptides in membranes by multidimensional solidstate NMR spectroscopy. Biochim Biophys Acta 1999; 1462:157-183.
50. Ludtke SJ, He K, Wu Y, Huang HW. Cooperative membrane insertion of magainin correlated with its cytolytic activity. Biochim Biophys Acta 1994; 1190:181-184.
51. Park JM, Jung JE, Lee BJ. Antimicrobial peptides from the skin of a Korean frog, Rana rugosa. Biochem Biophys Res Commun 1994; 205:948-954.
52. Oren Z, Shai Y. Mode of action of linear amphipathic α-helical antimicrobial peptides. Biopolymers 1998; 47:451-463.
53. Won HS, Jung SJ, Kim HE, Seo MD, Lee BJ, et al. Systematic peptide engineering and structural characterization to search for the shortest antimicrobial peptide analogue of gaegurin 5. J Biol Chem 2004; 279:14784-14791.
54. Won HS, Park SH, Kim HE, Hyun B, Kim M, Lee BJ, Lee BJ. Effects of a tryptophanyl substitution on the structure and antimicrobial activity of c-terminally truncated gaegurin 4. Eur J Biochem 2002; 269:4367-4374.
55. Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 2005; 62:784-790.
56. Rozek T, Wegener KL, Bowie JH, Olver IN, Carver JA, Wallace JC, Tyler MJ. The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis. The solution structure of aurein 1.2. Eur J Biochem 2000; 267:5330-5341.
57. Wegener KL, Wabnitz PA, Carver JA, Bowie JH, Chia BCS, Wallace JC, et al. Host defence peptides from the skin glands of the Australian Blue Mountains tree frog Litoria citropa. Solution structure of the antibacterial peptide citropin 1.1. Eur J Biochem 1999; 265:627-637.
58. Wegener KL, Brinkworth CS, Bowie JH, Wallace JC, Tyler MJ. Bioactive dahlein peptides from the skin secretions of the Australian aquatic frog Litoria dahlii: sequence determination by electrospray mass spectrometry. Rapid Commun Mass Spectrom 2001; 15:1726-1734.
59. Rozek T, Waugh RJ, Steinborner ST, Bowie JH, Tyler MJ, Wallace JC. The maculatin peptides from the skin glands of the tree frog Litoria genimaculata - a comparison of the structures and antibacterial activities of maculatin 1.1 and caerin 1.1. J Peptide Sci 1998; 4:111-115.
60. Bowie JH, Chia BCS, Tyler MJ. Host defence peptides from the skin glands of Australian amphibians: a powerful chemical arsenal. Pharmacol News 1998; 5:16-21.
61. Doyle J, Brinkworth CS, Wegener KL, Carver JA, Llewellyn LE, Olver IN, et al. nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications. The solution structure of a modified citropin 1.1. Eur J Biochem 2003; 270:1141-1153.
62. Rozek T, Bowie JH, Wallace JC, Tyler MJ. The antibiotic and anticancer active aurein peptides from the Australian Bell frogs Litoria aurea and Litoria raniformis. Part 2. Sequence determination using electrospray mass spectrometry. Rapid Commun Mass Spectrom 2000; 14:2002-2011.
63. Nitta K, Takayanagi G, Kawauchi H, Hakomori S. Isolation and characterization of Rana catesbeiana lectin and demonstration of lectin-binding glycoprotein of rodent and human cell membranes. Cancer Res 1987; 47:4877-4883.
64. Sakakibara F, Kawauchi H, Takayanagi G, Ise H. Egg lectin of Rana japonica and its receptor glycoprotein of Ehrlich tumour cells. Cancer Res 1979; 39:1347-1352.
65. Nitta K, Oyama F, Oyama R, Sekiguchi K, Kawauchi H, Takayanagi Y, et al. Ribonuclease activity of a sialic acid binding lectin from Rana catesbeiana. Glycobiol 1993; 3:37-45.
66. Titani K, Takio K, Kuwada M, Nitta K, Sakakibara F, Kawauchi H, et al. Amino acid sequence of sialic acid binding lectin from frog (Rana catesbeiana). Biochemistry 1987; 26:2198-2194.
67. Kamiya Y, Oyama F, Oyama R, Sakakibara F, Nitta K, Kawauchi H, et al. Amino acid sequence of a lectin from Japanese frog (Rana japonica) eggs. J Biochem (Tokyo) 1990; 108:139-143.
68. Ardelt W, Mikulski M, Shogen K. Amino acid sequence of an anti-tumour protein from Rana pipiens oocytes and early embryos. J Biol Chem 1991; 266:245-251.
69. Singh UP, Ardelt W, Saxena SK, Holloway DE, Vidunas E, Lee HS, et al. Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes. J Mol Biol 2007; 371:93-111.
70. Ilinskaya ON, Makarov AA. Why ribonucleases induce tumour cell death. Mol Biol 2005;39:1-10.
71. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt W, Shogen K. Cytostatic and cytotoxic effects of pannon (p-30 protein), a model anti-cancer agent. Cell Tissue Kinet 1988; 21:169-182.
72. Mikulski SM, Viera A, Ardelt W, Menduke H, Shogen K. Tamoxifen and trifluoroperazine (stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumour activity. Cell Tissue Kinet 1990; 23:237-246.
73. Mikulski SM, Ardelt W, Shogen K, Bernstein EH, Menduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 1990; 82:151-153.
74. Mikulski SM, Viera A, Shogen K. In vitro synergism between a novel amphibian oocytic ribonuclease (onconase) and tamoxifen, lovastatin and cisplatin in human OVCAR-3 ovarian carcinoma cell line. Int J Oncol 1992; 1:779-785.
75. Mikulski SM, Viera A, Darzynkiewicz A, Shogen K. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 1992; 66:304-310.
76. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, et al. Phase II trial of a single weekly intravenous dose of rapirnase in patient with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274-281.
77. Pavlakis N, Vogelzang NJ. Ranpirnase-an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 2006; 6:391-399.
78. Youle RJ, D'Alessio G. Anti-tumour RNases. In: D'Alessio G, Riordan JF, editors. Ribonucleases, structures and functions. New York: Academic Press; 1997. pp. 491-514.
79. Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, et al. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumour ribonuclease. J Natl Cancer Inst 1996; 88:747-753.
80. Nitta K, Ozaki K, Ishikawa M, Furusawa S, Hosono M, Kawauchi H, et al. Inhibition of cell proliferation by Rana catesbeiana and Rana japonica lectins belonging to the ribonuclease superfamily. Cancer Res 1994; 54:920-927.
81. Smith MR, Newton DL, Mikulski SM, Rybak SM. Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases. Exp Cell Res 1999; 247:220-232.
82. Lee JE, Raines RT. Contribution of active-site residues to the function of onconase, a ribonuclease with antitumoural activity. Biochemistry 2003; 42:11443-11450.
83. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumour blood vessels. Cancer Res 2002; 62: 6132-6140.
84. Arnold U, Ulbrich-Hofmann R. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 2006; 28:1615-1622.
85. Haigis MC, Raines RT. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci 2003; 116:313-324.
86. Leland PA, Schultz W, Kim B-M, Raines RT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci 1998; 95:10407- 10412.
87. Rybak SM, Newton DL. Uncloaking RNases. Nat Biotechnol 1999; 17:408-408.
88. Rybak SM, Newton DL. Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res 1999; 253:325-335.